AI Summary
This article likely discusses the use of ERAP inhibitors in the treatment of autoimmune diseases and immuno-oncology. It may provide insights from medicinal chemistry perspectives on how these inhibitors can be used to target specific pathways involved in immune dysregulation and cancer. The research may be exploring the development of new therapeutic agents to modulate ERAP activity for clinical applications. The significance lies in the potential for novel treatment approaches in these challenging medical conditions.